Founded in 1916 and wholly owned by government under the name Commonwealth Serum Laboratories, CSL was privatised in 1994 and is headquartered in Melbourne.

CSL Limited is now a multinational specialty biotech company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions, with products such as blood plasma derivatives, vaccines, antivenom and cell culture reagents.

“While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average,” Raymond said.

GRAPH OF CSL

Important: This content has been prepared without taking account of the objectives, financial situation or needs of any particular individual. It does not constitute formal advice. Consider the appropriateness of the information in regard to your circumstances.